Shares of health-care companies were more or less flat as traders hedged their bets on the outlook for regulations.
Swiss biotech giant Roche Holding said its immunotherapy drug Tecentriq, taken in combination with its Avastin drug and other treatments, slowed the progression of lung cancer and helped patients live longer in a late-stage study. The drug is one of a new class for which investors have high hopes, and the trial results alleviated worries about Roche's vulnerability to generic competition.
Continue Reading Below
--Rob Curran, email@example.com
(END) Dow Jones Newswires
December 07, 2017 16:25 ET (21:25 GMT)